Analysis of changes in bacterial flora in the upper gastrointestinal tract due to administration of Rifxima

Analysis of changes in bacterial flora in the upper gastrointestinal tract due to administration of Rifxima - Analysis of changes in bacterial flora in the upper gastrointestinal tract due to administration of Rifxima

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044550

Enrollment

Registered

2021-07-01

Start date

2021-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with cirrhosis with hepatic encephalopathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: It is intended for those who have hepatic encephalopathy with hyperammonemia between the ages of 20 and 90 and who are scheduled to receive rifaximin and who undergo upper gastrointestinal endoscopy.

Exclusion criteria

Exclusion criteria: When the research subject offers to decline participation in the research or withdraws consent When the entire research is canceled When discontinuing due to unfavorable events such as side effects When the person in charge of research determines that it is appropriate to discontinue the research for other reasons.

Design outcomes

Primary

Measure	Time frame
Changes in the bacterial flora of gastrointestinal tract after administration of rifaximin	—

Countries

Japan

Contacts

Public ContactShunhei Yamashina

Juntendo University Gastroenterology

syamashi@juntendo.ac.jp+81339957685

Outcome results